Hodgkin lymphoma in 2026: frontline strategies, ctDNA, and treatment after relapse

This VJHemOnc podcast explores the latest advances in Hodgkin lymphoma, from evolving frontline treatment strategies to emerging approaches in relapsed and refractory disease. Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the final three-year results from the AVENUE study (NCT03617666) and the role of circulating tumor DNA (ctDNA) in guiding treatment de-escalation. Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, compares BrECADD and Nivo-AVD for advanced-stage disease, while Sven Borchmann, MD, University Hospital Cologne, Cologne, Germany, highlights the prognostic value of ctDNA-based measurable residual disease assessment. Guilherme Perini, MD, Hospital Israelita Albert Einstein, São Paulo, Brazil, reviews the Phase II KEYFORM-008 trial (NCT05508867) investigating dual LAG-3 and PD-1 blockade in relapsed or refractory classical Hodgkin lymphoma, and Cathy Burton, MB BChir, MD, MRCP, FRCPath, St James's University Hospital, Leeds, UK, discusses treatment sequencing after checkpoint inhibition and the evolving role of autologous stem cell transplantation.